IP Library Granted Patent US 10,844,352
Granted Patent B2
US 10,844,352 · App. 15/527,334 · Granted Nov 24, 2020

Compositions and methods for the generation of melanocytes through direct reprogramming

Inventors: Xiaowei Xu (Monmouth Junction, NJ); Ruifeng Yang (Philadelphia, PA)
Assignee: The Trustees Of The University of Pennsyivania
C12N5/0626A61K35/36A61L27/3813A61L27/3839A61L27/3886A61L27/3895A61L27/54A61L27/58A61L27/60A61P17/00G01N33/5023A61L2300/64A61L2430/34C12N2501/01C12N2501/115C12N2501/125C12N2501/365C12N2501/60C12N2506/1307C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,844,352
App. No.
15/527,334
Granted
Nov 24, 2020
Kind
B2
Abstract

Compositions and methods for generating melanocytes through direct reprogramming are disclosed. Also disclosed are methods of use of such compositions for the treatment of vitiligo and other hypopigmentation disorders. In accordance with the present invention, a method for producing melanocytes suitable for use in human patients is provided. An exemplary method comprises providing cells capable of transdifferentiation into melanocytes, culturing said cells in a chemically defined culture medium, introducing at least two of microphthalmia-associated transcription factor (MITF), SRY-related HMG-box (SOX10) transcription factor and paired box-3 (PAX-3) transcription factor and paired box-3 (PAX-3) transcription factor, or nucleic acids encoding said transcription factors into said cells, wherein expression of said factors induces the cells to transdifferentiae into melanocytes expressing melanocyte markers TYR, DCT, S-100 and Melan-A.

Claims (13)

1. A method for producing melanocytes comprising:

a) providing fibroblast cells capable of transdifferentiation into melanocytes;

b) culturing said fibroblast cells in melanocyte culture medium for transdifferentiation;

c) introducing nucleic acids encoding each of at least microphthalmia-associated transcription factor (MITF), and SRY-related HMG-box (SOX10) transcription factors and, optionally a nucleic acid encoding paired box-3 (PAX-3) transcription factor, into said cells, wherein said transcription factors are expressed to cause transdifferentiation into melanocytes expressing melanocyte markers TYR, DCT, S-100 and Melan-A; and, optionally

d) isolating said melanocytes.

2. The method of claim 1 , wherein nucleic acid encoding all three transcription factors are introduced.

3. The method of claim 1 , wherein said cells are mammalian in origin.

4. The method of claim 3 , wherein said cells are human in origin.

5. The method of claim 2 , wherein said fibroblast cells are fetal or adult fibroblasts.

6. The method of claim 1 , wherein said transcription factors are encoded by one or more recombinant expression vectors.

7. The method of claim 1 , wherein said nucleic acid is synthetic mRNA.

8. The method of claim 1 , where is said culture media comprises Dulbecco's modified Eagle medium, fetal bovine serum, non-essential amino acids, sodium pyruvate and penicillin/streptomycin.

9. The method of claim 1 , wherein said fibroblasts cells are obtained from a patient in need of treatment with melanocytes.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 24, 2017
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044510/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2017
From: XU, XIAOWEI; YANG, RUIFENG
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 043445/0884 →
Continuity (2)
Provisional Application 62081228 · Nov 18, 2014
Related Publication 20190002827A1 · Jan 3, 2019